MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, OPCH had -$179,941K decrease in cash & cash equivalents over the period. $217,140K in free cash flow.

Cash Flow Overview

Change in Cash
-$179,941K
Free Cash flow
$217,140K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Infusion services net revenue
    • Proceeds from issuance of debt
    • Other revenue
    • Others
Negative Cash Flow Breakdown
    • Cost of net revenues - drugs
    • Salaries, benefits, and other em...
    • Other segment items
    • Others

Cash Flow
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Infusion services net revenue
5,555,778 ---
Other revenue
93,741 ---
Total option care health revenue
5,649,519 ---
Cost of net revenues - drugs
3,984,955 ---
Salaries, benefits, and other employee expense
848,996 ---
Other segment items
410,124 ---
Depreciation and amortization expense
67,538 ---
Interest expense, net
54,558 ---
Total option care health revenue
-4,998,202 --
Equity in earnings of joint ventures
7,409 ---
Cost of net revenues - drugs
-3,446,735 --
Other, net
-7,857 ---
Salaries, benefits, and other employee expense
-787,922 --
Other segment items
-380,803 --
Depreciation and amortization expense
-60,909 --
Interest expense, net
-49,029 --
Equity in earnings of joint ventures
-5,964 --
Other, net
-4,831 --
Income tax expense
75,315 71,776 --
Net income
207,585 211,823 267,090 150,556
Depreciation and amortization expense
70,690 63,498 62,200 65,434
Non-cash operating lease costs
25,008 22,581 18,533 19,713
Deferred income taxes, net
8,443 12,656 12,766 49,187
Gain on sale of assets
-0 0 9,403
Loss on extinguishment of debt
-4,744 -377 0 0
Amortization of deferred financing costs
4,147 4,628 4,446 4,304
Loss on interest rate swaps upon discontinuing hedge accounting
---0
Paid-in-kind interest capitalized as principal
---0
Equity in earnings of joint ventures
7,409 5,964 5,530 5,125
Stock-based incentive compensation expense
39,956 36,143 30,479 16,783
Distribution from equity method investments
4,000 2,400 4,000 5,875
Change in contingent consideration liability
---0
Other adjustments
1,033 -4,504 -1,244 0
Accounts receivable, net
54,593 32,075 -224 36,889
Inventories
81,469 114,127 51,000 41,010
Prepaid expenses and other current assets
-17,756 15,601 6,290 16,798
Accounts payable
19,523 183,395 47,703 98,885
Accrued compensation and employee benefits
6,292 -29,480 15,546 -7,770
Accrued expenses and other current liabilities
9,894 6,133 -1,727 10,535
Operating lease liabilities
24,034 21,911 17,529 21,395
Other noncurrent assets and liabilities
-6,881 -3,420 8,372 15,335
Net cash provided by operating activities
258,447 323,392 371,295 267,547
Acquisition of property and equipment
41,307 35,606 41,866 35,358
Proceeds from sale of assets
0 0 3,743 14,670
Business acquisitions, net of cash acquired
117,247 0 12,494 87,364
Other investing activities
2,529 864 5,889 0
Net cash used in investing activities
-161,083 -36,470 -56,506 -108,052
Exercise of stock options, vesting of restricted stock, and related tax withholdings
---3,115 352
Stock-based compensation tax withholdings
10,599 12,382 --
Net proceeds from issuance of common stock
---0
Purchase of company stock and related excise taxes
309,951 252,726 250,261 -
Proceeds from warrant exercises
-0 0 20,916
Proceeds from issuance of debt
229,472 49,959 0 0
Repayments of debt principal
4,951 6,384 6,000 6,000
Retirement of debt obligations
180,239 -0 0
Deferred financing costs
3,382 77 0 0
Debt prepayment fees
--0 0
Other financing activities
2,345 3,404 -5,750 -
Net cash used in financing activities
-277,305 -218,206 -265,126 15,268
Net (decrease) increase in cash and cash equivalents
-179,941 68,716 49,663 174,763
Cash and cash equivalents - beginning of period
412,565 343,849 294,186 119,423
Cash and cash equivalents - end of period
232,624 412,565 343,849 294,186
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Infusion services netrevenue$5,555,778K (13.12%↑ Y/Y)Other revenue$93,741K Total option carehealth revenue$5,649,519K (13.03%↑ Y/Y)Equity in earnings ofjoint ventures$7,409K (24.23%↑ Y/Y)Net income$207,585K (-2.00%↓ Y/Y)Depreciation andamortization expense$70,690K (11.33%↑ Y/Y)Canceled cashflow$5,449,343K Stock-based incentivecompensation expense$39,956K (10.55%↑ Y/Y)Non-cash operating leasecosts$25,008K (10.75%↑ Y/Y)Accounts payable$19,523K (-89.35%↓ Y/Y)Prepaid expenses andother current assets-$17,756K (-213.81%↓ Y/Y)Accrued expenses andother current...$9,894K (61.32%↑ Y/Y)Deferred income taxes,net$8,443K (-33.29%↓ Y/Y)Other noncurrentassets and liabilities-$6,881K (-101.20%↓ Y/Y)Accrued compensationand employee...$6,292K (121.34%↑ Y/Y)Loss onextinguishment of debt-$4,744K (-1158.36%↓ Y/Y)Amortization of deferredfinancing costs$4,147K (-10.39%↓ Y/Y)Distribution from equitymethod investments$4,000K (66.67%↑ Y/Y)Other adjustments$1,033K (122.94%↑ Y/Y)Net cash provided byoperating activities$258,447K (-20.08%↓ Y/Y)Canceled cashflow$167,505K Cost of net revenues -drugs$3,984,955K (15.62%↑ Y/Y)Salaries, benefits, andother employee...$848,996K (7.75%↑ Y/Y)Other segment items$410,124K (7.70%↑ Y/Y)Income tax expense$75,315K (4.93%↑ Y/Y)Depreciation andamortization expense$67,538K (6.36%↑ Y/Y)Interest expense, net$54,558K (11.28%↑ Y/Y)Other, net-$7,857K (-262.64%↓ Y/Y)Net (decrease)increase in cash and cash...-$179,941K (-361.86%↓ Y/Y)Canceled cashflow$258,447K Proceeds from issuance ofdebt$229,472K (359.32%↑ Y/Y)Other financingactivities$2,345K (-31.11%↓ Y/Y)Inventories$81,469K (-28.62%↓ Y/Y)Accounts receivable, net$54,593K (70.20%↑ Y/Y)Operating leaseliabilities$24,034K (9.69%↑ Y/Y)Equity in earnings ofjoint ventures$7,409K (24.23%↑ Y/Y)Net cash used infinancing activities-$277,305K (-27.08%↓ Y/Y)Canceled cashflow$231,817K Net cash used ininvesting activities-$161,083K (-341.69%↓ Y/Y)Purchase of company stockand related excise...$309,951K (22.64%↑ Y/Y)Retirement of debtobligations$180,239K Stock-based compensationtax withholdings$10,599K (-14.40%↓ Y/Y)Repayments of debtprincipal$4,951K (-22.45%↓ Y/Y)Deferred financing costs$3,382K (4292.21%↑ Y/Y)Business acquisitions,net of cash acquired$117,247K Acquisition of property andequipment$41,307K (16.01%↑ Y/Y)Other investingactivities$2,529K (192.71%↑ Y/Y)

2020 Annual Report on Form 10-K-1-pdf-svg

Option Care Health, Inc. (OPCH)

2020 Annual Report on Form 10-K-1-pdf-svg

Option Care Health, Inc. (OPCH)